These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 33242561)

  • 1. The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research.
    Gill H; Gill B; Rodrigues NB; Lipsitz O; Rosenblat JD; El-Halabi S; Nasri F; Mansur RB; Lee Y; McIntyre RS
    Neurosci Biobehav Rev; 2021 Jan; 120():78-85. PubMed ID: 33242561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression.
    Liu W; Zhou Y; Zheng W; Wang C; Zhan Y; Lan X; Zhang B; Li H; Chen L; Ning Y
    J Affect Disord; 2019 Dec; 259():1-6. PubMed ID: 31430662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression.
    Shiroma PR; Thuras P; Wels J; Albott CS; Erbes C; Tye S; Lim KO
    J Affect Disord; 2020 Dec; 277():470-477. PubMed ID: 32871534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurocognitive Effects of Ketamine and Esketamine for Treatment-Resistant Major Depressive Disorder: A Systematic Review.
    Souza-Marques B; Santos-Lima C; Araújo-de-Freitas L; Vieira F; Jesus-Nunes AP; Quarantini LC; Sampaio AS
    Harv Rev Psychiatry; 2021 Sep-Oct 01; 29(5):340-350. PubMed ID: 34366408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurocognitive impact of ketamine treatment in major depressive disorder: A review on human and animal studies.
    Crisanti C; Enrico P; Fiorentini A; Delvecchio G; Brambilla P
    J Affect Disord; 2020 Nov; 276():1109-1118. PubMed ID: 32777649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression.
    McMullen EP; Lee Y; Lipsitz O; Lui LMW; Vinberg M; Ho R; Rodrigues NB; Rosenblat JD; Cao B; Gill H; Teopiz KM; Cha DS; McIntyre RS
    Adv Ther; 2021 Jun; 38(6):2795-2820. PubMed ID: 33929660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurocognitive effects of repeated ketamine infusion treatments in patients with treatment resistant depression: a retrospective chart review.
    Dai D; Miller C; Valdivia V; Boyle B; Bolton P; Li S; Seiner S; Meisner R
    BMC Psychiatry; 2022 Feb; 22(1):140. PubMed ID: 35193541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression.
    Chen MH; Lin WC; Wu HJ; Bai YM; Li CT; Tsai SJ; Hong CJ; Tu PC; Cheng CM; Su TP
    CNS Spectr; 2021 Aug; 26(4):362-367. PubMed ID: 32419678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression.
    Zavaliangos-Petropulu A; McClintock SM; Khalil J; Joshi SH; Taraku B; Al-Sharif NB; Espinoza RT; Narr KL
    J Affect Disord; 2023 Jul; 333():161-171. PubMed ID: 37060953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review.
    Ng J; Rosenblat JD; Lui LMW; Teopiz KM; Lee Y; Lipsitz O; Mansur RB; Rodrigues NB; Nasri F; Gill H; Cha DS; Subramaniapillai M; Ho RC; Cao B; McIntyre RS
    J Affect Disord; 2021 Oct; 293():285-294. PubMed ID: 34225208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion.
    Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
    J Affect Disord; 2018 Dec; 241():1-7. PubMed ID: 30081380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review and meta-analysis of the efficacy of ketamine and esketamine on suicidal ideation in treatment-resistant depression.
    Wang YT; Wang XL; Lei L; Guo ZY; Kan FF; Hu D; Gai C; Zhang Y
    Eur J Clin Pharmacol; 2024 Feb; 80(2):287-296. PubMed ID: 38117332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: A comparative, randomized and double-blind study.
    Araújo-de-Freitas L; Santos-Lima C; Mendonça-Filho E; Vieira F; França RJAF; Magnavita G; Cardoso TL; Correia-Melo FS; Leal GC; Jesus-Nunes AP; Souza-Marques B; Marback R; Teles M; Echegaray MV; Beanes G; Guerreiro-Costa LNF; Mello RP; Rabanea T; Lucchese AC; Abreu N; Lacerda ALT; Quarantini LC
    Psychiatry Res; 2021 Sep; 303():114058. PubMed ID: 34153630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE).
    McIntyre RS; Rosenblat JD; Rodrigues NB; Lipsitz O; Chen-Li D; Lee JG; Nasri F; Subramaniapillai M; Kratiuk K; Wang A; Gill H; Mansur RB; Ho R; Lin K; Lee Y
    Psychiatry Res; 2021 Aug; 302():113993. PubMed ID: 34034067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Esketamine for treatment resistant depression.
    Swainson J; Thomas RK; Archer S; Chrenek C; MacKay MA; Baker G; Dursun S; Klassen LJ; Chokka P; Demas ML
    Expert Rev Neurother; 2019 Oct; 19(10):899-911. PubMed ID: 31282772
    [No Abstract]   [Full Text] [Related]  

  • 16. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety.
    Szarmach J; Cubała WJ; Włodarczyk A; Wiglusz MS
    Psychiatr Danub; 2019 Sep; 31(Suppl 3):585-590. PubMed ID: 31488795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.
    Rong C; Park C; Rosenblat JD; Subramaniapillai M; Zuckerman H; Fus D; Lee YL; Pan Z; Brietzke E; Mansur RB; Cha DS; Lui LMW; McIntyre RS
    Int J Environ Res Public Health; 2018 Apr; 15(4):. PubMed ID: 29673146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
    Jesus-Nunes AP; Leal GC; Correia-Melo FS; Vieira F; Mello RP; Caliman-Fontes AT; Echegaray MVF; Marback RF; Guerreiro-Costa LNF; Souza-Marques B; Santos-Lima C; Souza LS; Bandeira ID; Kapczinski F; Lacerda ALT; Quarantini LC
    Hum Psychopharmacol; 2022 Jul; 37(4):e2836. PubMed ID: 35179810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive changes in patients with unipolar TRD treated with IV ketamine: A systematic review.
    Grasso V; Gutierrez G; Alzbeidi N; Hernandorena C; Vázquez GH
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Dec; 135():111095. PubMed ID: 39032855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
    Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
    J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.